Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Kaiser

Showing results (181-190 of 206) with videos related to

Pageof 21
Sort By:
The Lancet. Oncology|December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood Cancer Journal|December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trialJ R Jones, D A Cairns, W M Gregory, et al.
Nature Communications|April 24, 2015
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaBrian A Walker, Christopher P Wardell, Alex Murison, et al.
Blood|October 31, 2018
Subclonal <i>TP53</i> copy number is associated with prognosis in multiple myelomaVallari Shah, David C Johnson, Amy L Sherborne, et al.
The Lancet. Haematology|October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Haematologica|February 9, 2019
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patientsJohn R Jones, Niels Weinhold, Cody Ashby, et al.
British Journal of Haematology|July 14, 2020
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Leukemia|June 7, 2017
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patientsV Shah, A L Sherborne, B A Walker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2016
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in MyelomaCharlotte Pawlyn, Martin F Kaiser, Christoph Heuck, et al.
Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Pageof 21

Showing results (181-190 of 206) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood Cancer Journal|December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trialJ R Jones, D A Cairns, W M Gregory, et al.
Nature Communications|April 24, 2015
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaBrian A Walker, Christopher P Wardell, Alex Murison, et al.
Blood|October 31, 2018
Subclonal <i>TP53</i> copy number is associated with prognosis in multiple myelomaVallari Shah, David C Johnson, Amy L Sherborne, et al.
The Lancet. Haematology|October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Haematologica|February 9, 2019
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patientsJohn R Jones, Niels Weinhold, Cody Ashby, et al.
British Journal of Haematology|July 14, 2020
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Leukemia|June 7, 2017
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patientsV Shah, A L Sherborne, B A Walker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2016
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in MyelomaCharlotte Pawlyn, Martin F Kaiser, Christoph Heuck, et al.
Plos Medicine|January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Pageof 21